Disruption and Maturity: The Next Evolution of Biologics

Since the widespread commercialization of the first recombinant protein, human insulin, biologic drugs have offered vast improvements in disease treatment and safety to high-need patients. This has driven their commercial success, biologics now representing half of the global top 20 drugs list, taking an increasing share of the market year on year.

The entrance of biosimilars signals the beginning into the next phase of biologics, continuing the journey to market maturity. This coincides with a particularly innovation productive period, with biologics offering step changes in disease treatment. This innovation is not limited to traditional biologic therapy areas such as oncology, but is expanding in to new high potential disease groups which have historically been treated using small molecule pharmaceuticals.

These trends combined cause the most dynamic market environment in biotechnology’s 40 year history. Pharmaco’s have invested heavily in the biotechnology space in an attempt to disrupt the market. Biosimilars threaten to wipe clean the current leading products. Players will have to launch strongly and partner effectively to keep up with the biologic industry’s high pace of innovation.

Please complete the form below to request our "Disruption and maturity: the next evolution of biologics" white paper.